SavedAdd your journal

Journals / Erciyes Tıp Dergisi / 2010 / Cilt: 32 - Sayı: 4

Retinopatisi olan tip 2 diabetes mellituslu olgularda serum paraksonaz aktivitesinin ve malondialdehit seviyelerinin belirlenmesi

The evaluation of serum paraoxanase activity and malondialdehyde levels in type 2 diabetic patients with retinopathy

Hatice ARDA
Sarper KARAKÜÇÜK
Koray GÜMÜŞ
Ertuğrul MİRZA
Gülden BAŞKOL
Ayşe ÖNER
Mevlüt BAŞKOL
Pages
235–240
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

When compared to healthy controls, there was a statistically significant decrease in serum basal PON1, stimulated PON 1 levels (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: In the present study, we aimed to evaluate paraoxonase1 (PON1) activities and malondialdehyde (MDA) levels, one of the end products of lipid peroxidation induced by reactive oxygen species in diabetic patients with retinopathy.Material and Methods: Serum MDA levels and PON1 levels were measured spectrophotometrically in 57 diabetic patients with retinopathy and in 24 healthy subjects which constituted the control group.Results: In the DM group, mean serum basal PON1, stimulated PON 1 and MDA levels are detected as 151.72 ± 76.26 U/L, 329.86 ± 234.05 U/L and 3.79 ± 2.11 nmol/mL, respectively.
📊
Key Findings & Data:In the control group, mean serum basal PON1, stimulated PON 1 and MDA levels are detected as 272.69 ± 104.44 U/L, 554.29 ± 214.58 U/L and 1.12 ± 0.29 nmol/mL, respectively.
💡
Conclusion & Impact:When compared to healthy controls, there was a statistically significant decrease in serum basal PON1, stimulated PON 1 levels (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: In the present study, we aimed to evaluate paraoxonase1 (PON1) activities and malondialdehyde (MDA) levels, one of the end products of lipid peroxidation induced by reactive oxygen species in diabetic patients with retinopathy.Material and Methods: Serum MDA levels and PON1 levels were measured spectrophotometrically in 57 diabetic patients with retinopathy and in 24 healthy subjects which constituted the control group.Results: In the DM group, mean serum basal PON1, stimulated PON 1 and MDA levels are detected as 151.72 ± 76.26 U/L, 329.86 ± 234.05 U/L and 3.79 ± 2.11 nmol/mL, respectively. In the control group, mean serum basal PON1, stimulated PON 1 and MDA levels are detected as 272.69 ± 104.44 U/L, 554.29 ± 214.58 U/L and 1.12 ± 0.29 nmol/mL, respectively. When compared to healthy controls, there was a statistically significant decrease in serum basal PON1, stimulated PON 1 levels (p

Özet

Amaç: Bu çalışmada Tip 2 diabetes mellituslu (DM) olgularda lipit peroksidasyonunun son ürünlerinden olan ve reaktif oksijen parçaları tarafından indüklenen, paraksonaz 1 (PON1) ve malondialdehit (MDA) seviyelerinin belirlenmesi amaçlanmıştır.Materyal ve Metod: Elli yedi diabetik olguda ve kontrol grubunu oluşturan 24 sağlıklı olguda serum MDA ve PON1 seviyeleri spektrofotometrik olarak ölçüldü.Bulgular: DM grubunda, ortalama serum bazal PON1 düzeyi 151,72 ± 76,26 U/L, ortalama stimüle PON 1 düzeyi 329,86 ± 234,05 U/L ve ortalama MDA düzeyi 3.79 ± 2.11 nmol/mL olarak bulundu. Kontrol grubunda ise ortalama serum bazal PON1 düzeyi 272,69 ± 104,44 U/L, ortalama stimüle PON 1 düzeyi 554,29 ± 214,58 U/L ve ortalama MDA düzeyi 1,12 ± 0.29 nmol/mL olarak bulundu. Diabetik olgularda serum bazal PON1 ve stimüle PON 1 düzeyleri sağlıklı kontrollere göre anlamlı olarak düşük saptanırken (p

🔖

Cite This Article

ARDA, H., KARAKÜÇÜK, S., GÜMÜŞ, K., MİRZA, E., BAŞKOL, G., ÖNER, A., BAŞKOL, M. (2022). Retinopatisi olan tip 2 diabetes mellituslu olgularda serum paraksonaz aktivitesinin ve malondialdehit seviyelerinin belirlenmesi. Erciyes Tıp Dergisi, Cilt: 32 - Sayı: 4, 235–240. https://ajindex.com/articles/502554

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Sundaram RK, Bhaskar A, Vijayalingham S, Viswanathan M, Mohan R, Shanmugasundaram KR. Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clin Sci (Lond) 1996; 90: 255–260
  2. Wohaieb SA, Godin DV. Alterations in free radical tissue-defense mechanisms in streptozotocin-induced diabetes in rat. Effects of insulin treatment. Diabetes 1987; 36: 1014–1018
  3. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991; 40: 405–412
  4. Maxwell SRJ, Thomason H, Sandler D, et al. Poor glycaemic control is associated with reduced serum free radical scavenging (antioxidant) activity in non-insulin- dependent diabetes mellitus. Ann Clin Biochem 1997; 34: 638–644
  5. La Du BN, Adkins S, Kuo CL, Lipsiq D. Studies on human serum paraoxonase/arylesterase. Chem Biol Interact 1993; 87: 25-34
  6. La Du BN. Structural and functional diversity of paraoxonases. Nat Med 1996; 2: 1186-87
  7. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76
  8. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high- density lipoprotein oxidation and preserves its functionÊ: a possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590
  9. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Rad Biol Med 2003; 34: 774-784
  10. Ayub A, Mackness MI, Arrol S, Mackness B, Patel J, Durrington PN. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol 1999; 19: 330-335
  11. Mackness MI, Harty D, Bhatnagar D, Winocour PH, Arrol S, Ishola M. Serum paraoxonase activity in familial hypercholesterolaemia and insulin dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-199
  12. Jain SK. Evidence for membrane lipid peroxidation during the in vivo aging of human erythrocytes. Biochem Biophys Acta 1998; 937: 205-210
  13. Eckerson HW, Romson J, Wyte C, La Du BN. The human serum paraoxonase polymorphism: identification of Phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-227
  14. Sözmen B, Delen Y, Girgin FK, Sözmen EY. Catalase and paraoxanase in hypertensive type 2 diabetes mellitus: correlation with glycemic control. Clinical Biochemistry 1999; 32: 423-427
  15. Ozmen B